Johnson & Johnson's first quarter 2026 revenue of $24.1B beat estimates, prompting a raised full-year outlook.

Johnson & Johnson reported first quarter 2026 revenue of $24.1 billion, up 9.9% year-over-year, with adjusted EPS of $2.70. Following the strong start to the year, the company raised its full-year 2026 guidance for both sales and adjusted EPS.

Key Highlights

• The company raised its full-year 2026 outlook, increasing its midpoint for estimated reported sales to $100.8 billion and for adjusted EPS to $11.55.
• The Innovative Medicine segment grew operational sales by 7.4% to $15.4 billion, driven by strong performance in Oncology and TREMFYA, which helped offset an approximate 920 basis point negative impact from Stelara competition.
• The MedTech segment delivered 4.6% operational sales growth, led by strength in Cardiovascular and Orthopaedics trauma products.